Neuromyelitis Optica

Positive Results for Soliris in Neuromyelitis Optica Spectrum Disorder Trial

Positive Results for Soliris in Neuromyelitis Optica Spectrum Disorder Trial

By

In the PREVENT study, the safety and efficacy of Soliris was compared to placebo in patients with AQP4 auto antibody-positive NMOSD (N=143).

Increased Neuromyelitis Optica Spectrum Disorder Relapse Risk in Postpartum Period

Increased Neuromyelitis Optica Spectrum Disorder Relapse Risk in Postpartum Period

By

The researchers suggest future prospective studies of acute relapse and disease-modifying treatment courses during and after pregnancy to ultimately improve treatment regimens for patients with NMOSD.

Differentiating Multiple Sclerosis Mimics on MRI

Differentiating Multiple Sclerosis Mimics on MRI

By

A proper MS diagnosis can only be made after obtaining imaging from the entire brain and understanding the clinical context.

Risk of Miscarriage, Preeclampsia Greater in Neuromyelitis Optica Spectrum Disorder

Risk of Miscarriage, Preeclampsia Greater in Neuromyelitis Optica Spectrum Disorder

By

In women with NMOSD, 42.9% of pregnancies ended in miscarriage compared with 12-24% in the general population.

Sign Up for Free e-newsletters



CME Focus